CN104053655A - 独脚金内酯和独脚金内酯类似物在治疗增殖性病症中的用途 - Google Patents

独脚金内酯和独脚金内酯类似物在治疗增殖性病症中的用途 Download PDF

Info

Publication number
CN104053655A
CN104053655A CN201280054089.9A CN201280054089A CN104053655A CN 104053655 A CN104053655 A CN 104053655A CN 201280054089 A CN201280054089 A CN 201280054089A CN 104053655 A CN104053655 A CN 104053655A
Authority
CN
China
Prior art keywords
methyl
cells
strigolactone
indol
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280054089.9A
Other languages
English (en)
Chinese (zh)
Inventor
约拉姆·卡普尼科
希南尼特·科尔泰
罗尼特·亚登
克里斯蒂娜·普兰迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agricultural Research Organization
Georgetown University
Original Assignee
Agricultural Research Organization
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agricultural Research Organization, Georgetown University filed Critical Agricultural Research Organization
Publication of CN104053655A publication Critical patent/CN104053655A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280054089.9A 2011-09-21 2012-09-20 独脚金内酯和独脚金内酯类似物在治疗增殖性病症中的用途 Pending CN104053655A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161537062P 2011-09-21 2011-09-21
US61/537,062 2011-09-21
US201261614965P 2012-03-23 2012-03-23
US61/614,965 2012-03-23
PCT/IL2012/050381 WO2013042124A1 (en) 2011-09-21 2012-09-20 Use of strigolactones and strigolactone analogs for treating proliferative conditions

Publications (1)

Publication Number Publication Date
CN104053655A true CN104053655A (zh) 2014-09-17

Family

ID=47913975

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280054089.9A Pending CN104053655A (zh) 2011-09-21 2012-09-20 独脚金内酯和独脚金内酯类似物在治疗增殖性病症中的用途

Country Status (7)

Country Link
US (1) US10208007B2 (https=)
EP (1) EP2758392B1 (https=)
JP (1) JP2014527979A (https=)
CN (1) CN104053655A (https=)
CA (1) CA2849343C (https=)
IN (1) IN2014CN02680A (https=)
WO (1) WO2013042124A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108558796A (zh) * 2018-05-07 2018-09-21 南开大学 一类羟亚甲基氢化茚酮衍生物及其制备方法和用途
CN108675974A (zh) * 2018-05-07 2018-10-19 南开大学 一类独脚金内酯衍生物及其制备方法和用途
CN109641883A (zh) * 2016-09-13 2019-04-16 先正达参股股份有限公司 植物生长调节剂化合物
CN117843651A (zh) * 2024-01-03 2024-04-09 盐城工学院 一种含有三氟甲基季碳中心的四氢呋喃并[3,2-b]吲哚啉类化合物及其制备方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3041479B1 (en) 2013-09-06 2023-04-26 Vanda Pharmaceuticals Inc. Treatment of cyr61- and vegf-mediated conditions
EP3294063A4 (en) * 2015-05-14 2018-12-05 The State of Israel, Ministry of Agriculture and Rural Development, Agricultural Research Organisation, Volcani Center Plant hormone application
EP3876927A1 (en) * 2018-11-08 2021-09-15 Universita' Degli Studi di Torino Strigolactones for use in preventing and/or treating infections caused by viruses of the herpesviridae family

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080318773A1 (en) * 2004-02-10 2008-12-25 Guillaume Becard Modulators of the Development of Mychorrizal Fungi with Arbuscules, and Uses Thereof
CN101730469A (zh) * 2007-06-15 2010-06-09 拜尔农科股份有限公司 包含独角金萌发素内酯衍生物和杀真菌剂化合物的农药组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200904331A (en) * 2007-06-15 2009-02-01 Bayer Cropscience Sa Pesticidal composition comprising a strigolactone derivative and an insecticide compound
EP2248421A1 (en) * 2009-05-07 2010-11-10 GMI - Gregor-Mendel-Institut für Molekulare Pflanzenbiologie GmbH Accumulation of biomass in plants
FI20106119A0 (fi) * 2010-10-27 2010-10-27 Sirtuin Valley Oy Energia-aineenvaihduntaan vaikuttava koostumus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080318773A1 (en) * 2004-02-10 2008-12-25 Guillaume Becard Modulators of the Development of Mychorrizal Fungi with Arbuscules, and Uses Thereof
CN101730469A (zh) * 2007-06-15 2010-06-09 拜尔农科股份有限公司 包含独角金萌发素内酯衍生物和杀真菌剂化合物的农药组合物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
C. B. POLLOCK，等: "Strigolactones: a novel class of phytohormones that inhibit the growth and survival of breast cancer cells and breast cancer stem-like enriched mammosphere cells", 《BREAST CANCER RES TREAT》 *
CRISTINA PRANDI，等: "New Potent Fluorescent Analogues of Strigolactones: Synthesis and Biological Activity in Parasitic Weed Germination and Fungal Branching", 《EUR. J. ORG. CHEM.》 *
EVGENIA DOR，等: "The synthetic strigolactone GR24 influences the growth pattern of phytopathogenic fungi", 《PLANTA》 *
JUAN C. G. GALINDO，等: "SAR Studies of Sesquiterpene Lactones as Orobanche Cumana Seed Germination Stimulants", 《J. AGRIC. FOOD CHEM.》 *
KOHKI AKIYAMA，等: "Structural Requirements of Strigolactones for Hyphal Branching in AM Fungi", 《PLANT CELL PHYSIOL.》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109641883A (zh) * 2016-09-13 2019-04-16 先正达参股股份有限公司 植物生长调节剂化合物
CN109641883B (zh) * 2016-09-13 2022-12-16 先正达参股股份有限公司 植物生长调节剂化合物
CN108558796A (zh) * 2018-05-07 2018-09-21 南开大学 一类羟亚甲基氢化茚酮衍生物及其制备方法和用途
CN108675974A (zh) * 2018-05-07 2018-10-19 南开大学 一类独脚金内酯衍生物及其制备方法和用途
CN108558796B (zh) * 2018-05-07 2020-04-07 南开大学 一类羟亚甲基氢化茚酮衍生物及其制备方法和用途
CN108675974B (zh) * 2018-05-07 2020-04-07 南开大学 一类独脚金内酯衍生物及其制备方法和用途
CN117843651A (zh) * 2024-01-03 2024-04-09 盐城工学院 一种含有三氟甲基季碳中心的四氢呋喃并[3,2-b]吲哚啉类化合物及其制备方法

Also Published As

Publication number Publication date
US10208007B2 (en) 2019-02-19
CA2849343A1 (en) 2013-03-28
WO2013042124A1 (en) 2013-03-28
WO2013042124A8 (en) 2013-07-25
US20140323563A1 (en) 2014-10-30
IN2014CN02680A (https=) 2015-07-03
EP2758392A4 (en) 2015-05-20
EP2758392B1 (en) 2019-09-18
CA2849343C (en) 2020-12-15
JP2014527979A (ja) 2014-10-23
EP2758392A1 (en) 2014-07-30

Similar Documents

Publication Publication Date Title
CN104053655A (zh) 独脚金内酯和独脚金内酯类似物在治疗增殖性病症中的用途
US10231939B2 (en) Hydroxytyrosol and oleuropein compositions for induction of DNA damage, cell death and LSD1 inhibition
Lin et al. DNA damage and endoplasmic reticulum stress mediated curcumin-induced cell cycle arrest and apoptosis in human lung carcinoma A-549 cells through the activation caspases cascade-and mitochondrial-dependent pathway
WO2018215795A2 (en) Senolytic compounds
Tang et al. Inhibition of angiogenesis and invasion by DMBT is mediated by downregulation of VEGF and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells
Zhang et al. Silibinin inhibited autophagy and mitochondrial apoptosis in pancreatic carcinoma by activating JNK/SAPK signaling
Ma et al. IPM712, a vanillin derivative as potential antitumor agents, displays better antitumor activity in colorectal cancers cell lines
Zhang et al. Isocryptotanshinone induced apoptosis and activated MAPK signaling in human breast cancer MCF-7 cells
Huang et al. Phyllanthus urinaria’s inhibition of human osteosarcoma xenografts growth in mice is associated with modulation of mitochondrial fission/fusion machinery
Kim et al. Anti-neuroinflammatory effect of Iresine celosia on lipopolysaccharide-stimulated microglial cells and mouse
US20250381166A1 (en) Cannabis-Derived Flavonoids And Related Methods
AU2015352041B2 (en) Titled extracts of Cynara scolymus and uses thereof
Hsu et al. 2-(3-Fluorophenyl)-6-methoxyl-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (YJC-1) induces mitotic phase arrest in A549 cells
TWI542348B (zh) 含４－乙醯基－安卓奎諾－ｂ之組合物用於製備抑制癌細胞生長之藥物的用途
ITRM20130502A1 (it) Estratto di filipendula vulgaris e suoi usi
JP2009013131A (ja) 細胞増殖抑制剤
ITRM20130312A1 (it) Estratto di cynara spp. e suoi usi.
WO2019142097A1 (en) Inhibitors of cxcr4 against senescence
Liu et al. Spatholobus suberectus Dunn inhibits breast cancer bone metastasis in vitro and in vivo
Wang Dietary Compound Diosmetin Chemosensitizes Breast Cancer Stem Cells by Suppressing HMGB1-mediated Autophagy
KR101416505B1 (ko) 마타이레시놀을 포함하는 혈관신생 억제용 약제학적 조성물
US20180221329A1 (en) Cis- and trans-suffruticosol d as therapeutic agents
CN105878253A (zh) 科罗索酸的医药用途
Zhang et al. The effect of methylseleninic acid on paclitaxel efficacy in A2780 ovarian cancer cells
TWI406658B (zh) 使用異硫氰酸酯類來治療癌症之方法及用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140917